A MediCom Oncology Site
This website uses cookies. By using our site you agree to our
privacy policy
Email:
Password:
Lost username/password
Create an account
Search ...
Home
About Us
Diagnosis
Treatment
CE Education
Eunice S. Wang, MD
Chief, Clinical Leukemia Service
Professor, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Last modified: April 12, 2022
Authored Items
A Focus on Prognostic Indicators for Treatment in Patients with AML
Eunice S. Wang, MD
Treatment
Published on
March 21, 2022
What are the latest updates in the Phase 3 study of gilteritinib and AZA vs AZA alone for ND FLT-3 AML in patients ineligible for induction chemotherapy?
Eunice S. Wang, MD
Treatment
Published on
February 28, 2022
What is the current thinking on waiting for genetic information before starting treatment?
Eunice S. Wang, MD
Treatment
Published on
February 23, 2022
Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?
Eunice S. Wang, MD
Treatment
Published on
December 7, 2020
What are the key factors you must take into consideration in determining upfront treatment for patients with high-risk, secondary AML?
Eunice S. Wang, MD
Treatment
Published on
November 30, 2020
